Sygnis strengthens management team with appointment of Heikki Lanckriet

He joins the DNA amplification and sequencing firm as joint CEO and Chief Scientific Officer

Sygnis, a DNA amplification and sequencing company, headquartered in Germany and Spain, has appointed Heikki Lanckriet as co-CEO and Chief Scientific Officer (CSO), a newly created position.

Lanckriet has also joined the Management Board of Sygnis, along with Pilar de la Huerta, who will be co-CEO and Chief Financial Officer (CFO) of the combined organisation.

Lanckriet co-founded Expedeon, a privately held proteomics tools and reagents company headquartered in the UK, in 2003.

At Expedeon, he was Chief Operating Officer, CSO and CEO, and accumulated extensive knowledge of the life sciences tools and reagents business.

Lanckriet holds a BSc and MSc in biochemical engineering from the University of Ghent, Belgium and a PhD in biochemical engineering from the University of Cambridge, UK.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now